Back to main site

Members

Clinical engagement

Lead: Stefan Englert (AbbVie)

Objective: Develop basic introductory material that can be used by all study team members to educate themselves on Oncology Estimands. Translate key messages from the working group activities to a non-statistical audience, targeting especially clinical functions.

Firstname Lastname Institution Location
Stefan Englert AbbVie EU
Feng Liu AstraZeneca NorAm
Jonathan Siegel Bayer NorAm
Emily Butler GSK NorAm
Rui Tang Servier NorAm
Paul Bycott US NorAm

Propensity scores for treatment switching

Lead: character(0) character(0) (character(0))

Objective: NA

Firstname Lastname Institution Location

Patient-reported outcomes

Lead: Rachael Lawrence (Adelphi)

Objective: Clarify what questions are we answering with typical analyses conducted on HRQoL endpoints in regulatory clinical trials. We are going to consider longitudinal mixed models and time to event analyses initially; “mapping” potential common questions into the estimand framework. The task force is also going to dig into the question of “how to handle death” in HRQoL analyses. We are keen to build collaborative approaches with statisticians and others active in this topic area, such as SISAQoL and ISOQoL working groups.

Firstname Lastname Institution Location
Rachael Lawrence Adelphi EU
Xiangning Huang AstraZeneca EU
Evgeny Degtyarev Novartis EU
Stephen Corson Phastar EU
Konstantina Skaltsa IQVIA Europe
Antoine Regnault Modus Outcomes Europe
Johan Bring Statisticon Europe
Jonathan Siegel Bayer NorAm
Libby Floden Solutions US
Stacie Hudgens Solutions US

Duration of responses

Lead: Hans-Jochen Weber (Novartis)

Objective: Duration of response and also time to response are standard secondary endpoints in clinical studies in oncology. There are different approaches for analysis and often the clinical question to be addressed remains unclear. We contextualize the different approaches using the estimand framework and illustrate those with case studies. Finally we intend to present recommendations for analyses targeting relevant clinical questions.

Firstname Lastname Institution Location
Alex Todd AstraZeneca EU
Martin-Oliver Sailer Boehringer EU
Hans-Jochen Weber Novartis EU
Stephen Corson Phastar EU
Francois Mercier Roche EU
Jiang Li Beigene NorAm
Steven Sun J&J NorAm
Satrajit Roychoudhury Pfizer NorAm
Godwin Yung Roche NorAm

Quantification of follow-up

Lead: Kaspar Rufibach (Roche)

Objective: Follow up is very heterogeneously quantified in oncological clinical trials. Given the importance assigned to “amount of follow up” in general the objective of this task force is to describe various ways how follow up is typically quantified, study its properties and issue recommendations how to report follow up and how to interpret it.

Firstname Lastname Institution Location
Lynda Grinsted AstraZeneca EU
Hans-Jochen Weber Novartis EU
Kaspar Rufibach Roche EU
Jiang Li Beigene NorAm
Jiangxiu Zhou GSK NorAm
Yue Shentu Merck NorAm
Cheng Zheng Sanofi NorAm

Real-world data and estimands

Lead: Evgeny Degtyarev (Novartis)

Objective: Illustrate the value and promote the use of target trial framework and estimand framework for design of comparisons including real-world data. The frameworks allows to clarify the definition of the causal question of interest ensuring alignment between the research objective and analysis. Its application in submission documents would facilitate regulatory review in a transparent and structured way.

Firstname Lastname Institution Location
Evgeny Degtyarev Novartis EU
Lisa Hampson Novartis EU
Kaspar Rufibach Roche EU
Feng Xiao AstraZeneca NorAm
Cheng Zheng Sanofi NorAm
Rui Tang Servier NorAm
Jianchang Lin Takeda NorAm
Paul Bycott US NorAm

Conditional vs. marginal effects

Lead: Jiawei Wei (Novartis)

Objective: We would like to bring the complex concept and methods about conditional and marginal treatment effect into a simplified and interpretable way. Potential topics including adjusted or unadjusted analysis; stratified vs unstratified hazard ratio; collapsibility and subgroup; p-values; etc. We will give clinically relevant opinions and recommendations based on our interpretation, and illustrate the idea using some case studies.

Firstname Lastname Institution Location
Jiajun Xu J&J Asia
Jiawei Wei Novartis Asia
Ziqiang Zhao Novartis Asia
Björn Bornkamp Novartis EU
Kaspar Rufibach Roche EU
Hong Tian J&J NorAm
Satrajit Roychoudhury Pfizer NorAm

Time to event endpoints with prognostic or predictive biomarker subgroups

Lead: Yi Liu (Nektar)

Objective: Our goal is to understand various efficacy estimands of biomarker subgroups and its relationship to the overall population for binary and time-to-event endpoints. For continuous outcomes with difference of means as efficacy estimand, Least Square estimates from the full model containing treatment, subgroup, and its interaction term enable an unbiased estimation of efficacy for the overall population by linearly combining estimands of the two subgroups. Following the same process for binary or time-to-event efficacy estimands such as hazard ratio or odds ratio, although guaranteeing logical inference in appearance, does not lead to the correct efficacy estimand of the overall population. In fact, the correct HR (or OR) may be outside of the interval of subgroup HRs (or ORs) leading to illogical interpretations. The task force will investigate which efficacy measures are logic respecting on the population level and make recommendations on how to analyze real clinical trial data so that analysis results based on these efficacy measures will always be logical for either prognostic or predictive biomarkers.

Firstname Lastname Institution Location
Siyoen Kil LSK Global Pharma Services Asia
Martin-Oliver Sailer Boehringer EU
Jonathan Siegel Bayer NorAm
Jiang Li Beigene NorAm
Shoubhik Mondal Boehringer NorAm
Hong Tian J&J NorAm
Liwei Wang J&J NorAm
Yue Shentu Merck NorAm
Yi Liu Nektar NorAm
Miao Yang Nektar NorAm
Godwin Yung Roche NorAm

Early development estimand nexus (EDEN)

Lead: Francois Mercier (Roche)

Objective: In oncology Phase 1a (dose-escalation) and Phase 1b (expansion cohort) studies, the designs are complex because the objectives are often multiple and ambitious. Defining estimands and the associated estimators in this setting can be difficult. In this WG, we intend to implement the ICH-E9 addendum and to reflect on the challenges it presents in early clinical development studies. Such challenges may include: (1) absence of control group (2) varying dose, but also dosing schedule across treatment arms (a.k.a. cohorts) (3) presence of anti-drug antibody (ADA) (4) prophylactic treatment or co-medication for toxicity mitigation (e.g. using steroids) (5) compassionate within-patient dose escalation. The taskforce will give clinically relevant opinions and recommendations based on our analysis and interpretation of the selected case studies. Contact to other task forces will be sought based on need.

Firstname Lastname Institution Location
Francois Mercier Roche EU